key: cord-0907905-u8n53ml1 authors: Lu, Cuicui; Hou, Ning title: Skin Hyperpigmentation in Coronavirus Disease 2019 Patients: Is Polymyxin B the Culprit? date: 2020-09-03 journal: Front Pharmacol DOI: 10.3389/fphar.2020.01304 sha: 3fdc4eb0e95887c1d8c3f70ff79e436a8b67b5be doc_id: 907905 cord_uid: u8n53ml1 nan for polymyxin B induced pigmentary disorder in critically ill patients with COVID-19, such as Fan Yi and Weifeng Hu. Diffuse skin hyperpigmentation was only reported in several cases (Zavascki et al., 2016) . Polymyxin B induced skin hyperpigmentation was mainly on the face and neck in most cases, while other parts of the body remained unchanged throughout the course of treatment (Zavascki et al., 2015; Mattos et al., 2016; Lahiry et al., 2017) . Interestingly, the density of melanocytes in the face and neck is higher than in other areas (Silpa-Archa et al., 2017) . Sun exposure was excluded as cause for skin hyperpigmentation as the exposed shoulders and arms were spared. Dermatologic manifestations are rare in COVID-19 confirmed cases. Among 1,099 hospitalized COVID-19 patients in Wuhan, only 0.2% presented with skin lesions (Guan et al., 2020) . There is no report so far about COVID-19 associated skin darkening. Maculopapular eruptions, pseudochilblain, and urticarial lesions are the most common cutaneous manifestations (Kaya et al., 2020) . Trunk and extremities are the main involved areas and lesions usually resolve spontaneously in a few days (Kaya et al., 2020; Recalcati, 2020) . Therefore, skin hyperpigmentation is unlikely to be caused by the novel coronavirus. In a cohort study, 60 patients treated with intravenous polymyxin B were followed up. Skin hyperpigmentation occurred in 15% of patients and the incidence was higher in darker-skinned patients than in Caucasian patients. Skin darkness was usually noted on the 3 rd day of treatment and decreased gradually after polymyxin B cessation (Mattos et al., 2016) . According to a prospective study, the incidence of skin hyperpigmentation was 8%. Skin changes also appeared on the 3 rd day of treatment and the pigmentary disorder became absolutely evident after 7 days of polymyxin B treatment (Mattos et al., 2017) . Whether skin hyperpigmentation will be completely resolved after discontinuation of polymyxin B remains controversial. It was reported that only a small part of the study population survived a few months after the end of the treatment (Mattos et al., 2017) . Gothwal S et al. reported one neonate restored to the original color on 45 days, but the other two neonates lost follow up (Gothwal et al., 2016) . It was shown in another study that skin darkness of a 46-year-old Hispanic man improved gradually but not reversed to the baseline, even after 5 months of treatment (Knueppel and Rahimian, 2007) . Fan Yi was discharged on May 9 and a partial recovery of skin color was noticed. Unfortunately, the condition of Weifeng Hu was deteriorated and he died on June 2. The pathogenesis of polymyxin B associated skin damage could be related to histamine release and inflammatory response. Histamine is stored primarily in human mast cells and basophils, while Polymyxin B can promote the release of the stored histamine (Lassalle et al., 2003; Mattos et al., 2017) . Yoshida et al. showed that histamine increased cAMP accumulation and protein kinase activity via H 2 receptors, resulting in the overexpression of melanin (Yoshida et al., 2000) . Lee et al. found that growth-differentiation factor-15 (GDF-15) was also involved in histamine-induced melanogenesis by increasing melanin production and chemotactic migration (Lee et al., 2012) . Furthermore, epidermal Langerhans cells are antigenpresenting cells, which play an important role in chronic skin inflammation. Histologic examinations were performed in several patients who suffered from polymyxin B induced skin hyperpigmentation, and hyperplasia of Langerhans cells in epidermis was found in their skin biopsies (Mattos et al., 2017) . Since histamine is also associated with inflammatory response, it is presumed that skin hyperpigmentation is a postinflammatory effect. So far, there has been no ideal preventive and therapeutic approaches for polymyxin B associated skin hyperpigmentation. Removal of provoking factors, laser cosmetic therapy and topical whitening agents could help recover as soon as possible. Although the outcome of therapy is not affected, skin darkness can cause mental stress and aesthetic damage. Healthcare workers should be aware of this rare adverse event, and skin color changes should be monitored frequently. Higher concentration of polymyxin B may be relevant to skin darkening in some studies (Zheng et al., 2018) . Once polymyxin B induced skin hyperpigmentation was observed, it was crucial to make dose adjustment or replace it with an alternative medication regimen. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant /extensively drug-resistant/pandrugresistant bacteria Acute kidney injury in critically ill patients with COVID-19 Drug-Induced Hyperpigmentation: Review and Case Series Polymyxin B Induced Generalized Hyperpigmentation in Neonates Clinical Characteristics of Coronavirus Disease 2019 in China Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature Diffuse Cutaneous Hyperpigmentation Due to Tigecycline or Polymyxin B Polymyxin B Induced Diffuse Cutaneous Hyperpigmentation Effects of melanogenesis-inducing nitric oxide and histamine on the production of eumelanin and pheomelanin in cultured human melanocytes Histamine receptor 2-mediated growth-differentiation factor-15 expression is involved in histamine-induced melanogenesis Polymyxin B-induced skin hyperpigmentation Is the kidney a target of SARS-CoV-2? Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study Skin hyperpigmentation following intravenous polymyxin B treatment associated with associated with melanocyte activation and inflammatory process An Update on Drug Induced Pigmentation COVID-19 Diagnosis and Management: A Comprehensive Review Cutaneous manifestations in COVID-19: a first perspective Clinical Use of Polymyxin B Management of acute kidney injury in patients with COVID-19 Postinflammatory hyperpigmentation: A comprehensive overview: Epidemiology, pathogenesis, clinical presentation, and noninvasive assessment technique Histamine induces melanogenesis and morphologic changes by protein kinase A activation via H2 receptors in human normal melanocytes Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy Histopathological Findings of Pigmented Lesion and Recovery of Natural Skin Colour in a Patient with Polymyxin B-associated Diffuse Hyperpigmentation Polymyxin Binduced Skin Hyperpigmentation: A Rare Case Report and Literature Review NH was responsible for the study conception and design. CL drafted the manuscript. NH revised and edited the manuscript. All authors contributed to the article and approved the submitted version.